Sabby Management LLC decreased its position in shares of Cytosorbents Corporation (NASDAQ:CTSO) by 21.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 172,100 shares of the medical research company’s stock after selling 47,900 shares during the quarter. Sabby Management LLC owned about 0.61% of Cytosorbents Corporation worth $740,000 as of its most recent SEC filing.

Separately, Skylands Capital LLC boosted its stake in Cytosorbents Corporation by 87.7% during the 2nd quarter. Skylands Capital LLC now owns 594,250 shares of the medical research company’s stock worth $2,555,000 after acquiring an additional 277,650 shares during the last quarter. 6.89% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/cytosorbents-corporation-ctso-position-trimmed-by-sabby-management-llc/1636904.html.

Several analysts have commented on the stock. Aegis restated a “buy” rating and set a $9.00 target price on shares of Cytosorbents Corporation in a report on Tuesday, July 25th. B. Riley restated a “buy” rating and set a $11.25 target price on shares of Cytosorbents Corporation in a report on Monday, August 7th. ValuEngine downgraded shares of Cytosorbents Corporation from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of Cytosorbents Corporation in a report on Tuesday, September 26th. Finally, Maxim Group restated a “buy” rating and set a $10.00 target price on shares of Cytosorbents Corporation in a report on Wednesday, July 5th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. Cytosorbents Corporation has a consensus rating of “Buy” and a consensus price target of $10.45.

Shares of Cytosorbents Corporation (NASDAQ:CTSO) remained flat at $6.15 during mid-day trading on Tuesday. The company had a trading volume of 53,509 shares. The company’s 50 day moving average price is $5.78 and its 200 day moving average price is $4.85. The firm’s market cap is $173.02 million. Cytosorbents Corporation has a 52 week low of $3.30 and a 52 week high of $6.70.

Cytosorbents Corporation (NASDAQ:CTSO) last posted its quarterly earnings results on Monday, August 7th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. The firm had revenue of $3.57 million for the quarter, compared to analysts’ expectations of $3.29 million. Cytosorbents Corporation had a negative return on equity of 529.95% and a negative net margin of 80.56%. Analysts forecast that Cytosorbents Corporation will post ($0.27) earnings per share for the current year.

Cytosorbents Corporation Profile

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Institutional Ownership by Quarter for Cytosorbents Corporation (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.